Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Repurposing drugs against main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data

Abstract

The ongoing global pandemic of COVID-19 has brought life to almost stand still with implementations of lockdown and social distancing as some of the preventive measures in the absence of any approved specific therapeutic interventions. To combat this crisis, research community world-wide are falling back on the existing repertoire of approved/investigational drugs to probe into their anti-coronavirus properties. In this report, we have described our unique efforts in identifying potential drugs that could be repurposed against main protease of SARS-CoV-2 (SARS-CoV-2 Mpro). To achieve this goal, we have primarily exploited the principles of ‘neighbourhood behaviour’ in protein 3D (workflow-I) and chemical 2D structural space (workflow-II) coupled with docking simulations and insights into the possible mode of actions of the selected candidates from available literature. Such an integrative approach culminated in prioritizing 29 potential repurpose-able agents (20 approved drugs and 9 investigational molecules) against SARS-CoV-2 Mpro. Apart from the approved/investigational anti-viral drugs, other notable hits include anti-bacterial, anti-inflammatory, anti-cancer and anti-coagulant drugs. Our analysis suggests that some of these drugs have the potential to simultaneously modulate the functions of viral proteins and host response system. Interestingly, many of these identified candidates (12 molecules from workflow-I and several molecules belonging to the chemical classes of alkaloids, tetracyclines, peptidomimetics from workflow-II) are suggested to possess anti-viral properties which are supported by laboratory and clinical data. Further, this work opens a new avenue of research to probe into the molecular mechanism of action of many drugs which are known to demonstrate anti-viral activity but are so far not known to target viral proteases.

Back to tab navigation

Supplementary files

Article information


Submitted
15 May 2020
Accepted
25 Jun 2020
First published
26 Jun 2020

Mol. Omics, 2020, Accepted Manuscript
Article type
Research Article

Repurposing drugs against main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data

S. Chakraborti, S. Bheemireddy and N. Srinivasan, Mol. Omics, 2020, Accepted Manuscript , DOI: 10.1039/D0MO00057D

Social activity

Search articles by author

Spotlight

Advertisements